A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Autor: Chatterjee, Manik, Raab, Marc S., Goldschmidt, Hartmut, Agis, Hermine, Blau, Igor Wolfgang, Einsele, Hermann, Engelhardt, Monika, Ferstl, Barbara, Günther, Andreas, Röllig, Christoph, Weisel, Katja, Jarutat, Tiantom, Weinelt, Dominika, Winderlich, Mark, Boxhammer, Rainer, Peschel, Christian
Zdroj: In Clinical Lymphoma Myeloma and Leukemia February 2017 17(1) Supplement:e61-e61
Databáze: ScienceDirect
Externí odkaz: